SARS-CoV-2 and Covid 19
Nanomaterial vaccines versus SARS-CoV-2
Although vaccines for SARS-CoV-2 are currently in development in industry, with at least one already in clinical trials, these vaccines are not guaranteed to function as desired, especially in patients with limited immune responses, such as the elderly. The Hubbell and Swartz Labs are collaboratively developing two nanomaterial vaccine platforms that they have shown can induce very broad neutralizing antibody responses in preliminary work with Lassa virus and malaria antigens.
Pulmonary targeting of inhibitors or viral replication and inflammatory cytokine production
Many central regulators of gene expression also impact expression of viral genes, limiting viral replication. Here, the Swartz and Hubbell Labs seek to develop drug formulations to efficiently target gene expression regulators to the airway epithelium, focusing on compounds that may modulate viral replication of SARS-CoV-2 and the effects thereof, such as expression of proinflammatory cytokines.